Stereotaxis, Inc. (STXS)

AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-23

$1.02+2.20%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Stereotaxis, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	Over $10M	10.73M
EPS	—	-0.04
FY 2026 · Annual
Revenue	$40M	34.33M
EPS	—	-0.207
FY 2027 · Annual
Revenue	—	45.67M
EPS	—	-0.15

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce losses and improve earnings	A supporting condition in Stereotaxis, Inc.'s published investment case. The stated target is EPS loss narrows toward -$0.13 or better by FY27.	Improving	EPS loss worsens or stays below -$0.19 in FY26	Diluted EPS: $-0.05 per share FY2026-Q2; GAAP. Published target: EPS loss narrows toward -$0.13 or better by FY27. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-0.05 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f745fd6f-b010-4f96-b2f8-b9a935db7298. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue exceeds $10 million in Q3 and Q4 2026	A primary condition in Stereotaxis, Inc.'s published investment case. The stated target is >= $10 million revenue each in Q3 and Q4 2026.	Broken	Revenue falls below $10 million in either Q3 or Q4 2026	Revenue: $7.67M FY2026-Q2; GAAP. Published target: >= $10 million revenue each in Q3 and Q4 2026. Target period is not explicitly aligned with this observation. Source published Aug 12, 20267,670,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f745fd6f-b010-4f96-b2f8-b9a935db7298. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve double-digit revenue growth in 2026	Stereotaxis aims for double-digit revenue growth in 2026.	Broken	YoY revenue growth falls below 8% in FY26	Revenue growth: -12.82% FY2026-Q2; GAAP. Published target: >=10% YoY revenue growth. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-12.821096 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f745fd6f-b010-4f96-b2f8-b9a935db7298. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $6.3 million in 2026-Q1 to $7.7 million in 2026-Q2. Management expects annual revenue to surpass $40 million in 2026 with continued momentum from manufacturing ramp and commercial adoption. The trajectory is delivering consistent growth aligned with management's stated goal. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	2 / 3
2026-07-26	Unavailable	Unavailable	2 / 3
2026-07-27	Unavailable	Unavailable	2 / 3
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	Unavailable	2 / 3
2026-07-30	Unavailable	Unavailable	2 / 3
2026-07-31	Unavailable	Unavailable	2 / 3
2026-08-01	Unavailable	Unavailable	2 / 3
2026-08-02	Unavailable	Unavailable	3 / 4
2026-08-03	Unavailable	Unavailable	3 / 4
2026-08-04	Unavailable	Unavailable	3 / 4
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	Unavailable	2 / 3
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	Unavailable	2 / 3
2026-08-12	Unavailable	Unavailable	2 / 3
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 2
2026-08-21	Unavailable	Unavailable	2 / 2
2026-08-22	Unavailable	Unavailable	2 / 2
2026-08-23	Unavailable	Unavailable	2 / 2
2026-08-24	Unavailable	Unavailable	2 / 2
2026-08-25	Unavailable	Unavailable	2 / 2
2026-08-26	Unavailable	Unavailable	2 / 2
2026-08-27	Unavailable	Unavailable	2 / 2
2026-08-28	Unavailable	Unavailable	2 / 2
2026-08-29	Unavailable	Unavailable	2 / 2
2026-08-30	Unavailable	Unavailable	2 / 2
2026-08-31	Unavailable	Unavailable	2 / 2
2026-09-01	Unavailable	Unavailable	2 / 2
2026-09-02	Unavailable	Unavailable	2 / 2
2026-09-03	Unavailable	Unavailable	2 / 2
2026-09-04	Unavailable	Unavailable	2 / 2
2026-09-05	Unavailable	Unavailable	2 / 2
2026-09-06	Unavailable	Unavailable	2 / 2
2026-09-07	Unavailable	Unavailable	2 / 2
2026-09-08	Unavailable	Unavailable	2 / 2
2026-09-09	Unavailable	Unavailable	2 / 2
2026-09-10	Unavailable	Unavailable	2 / 2
2026-09-11	Unavailable	Unavailable	2 / 2
2026-09-12	Unavailable	Unavailable	2 / 2
2026-09-13	Unavailable	Unavailable	2 / 2
2026-09-14	Unavailable	Unavailable	2 / 2
2026-09-15	Unavailable	Unavailable	2 / 2
2026-09-16	Unavailable	Unavailable	2 / 2
2026-09-17	Unavailable	Unavailable	2 / 2
2026-09-18	Unavailable	Unavailable	2 / 2
2026-09-19	Unavailable	Unavailable	2 / 2
2026-09-20	Unavailable	Unavailable	2 / 2
2026-09-21	Unavailable	Unavailable	2 / 2
2026-09-22	Unavailable	Unavailable	2 / 2
2026-09-23	Unavailable	Unavailable	2 / 2
2026-09-24	Unavailable	Unavailable	2 / 2
2026-09-25	Unavailable	Unavailable	2 / 2
2026-09-26	Unavailable	Unavailable	2 / 2
2026-09-27	Unavailable	Unavailable	2 / 2
2026-09-28	Unavailable	Unavailable	2 / 2
2026-09-29	Unavailable	Unavailable	2 / 2
2026-09-30	Unavailable	Unavailable	2 / 2
2026-10-01	Unavailable	Unavailable	2 / 2
2026-10-02	Unavailable	Unavailable	2 / 2
2026-10-03	Unavailable	Unavailable	2 / 2
2026-10-04	Unavailable	Unavailable	2 / 2
2026-10-05	Unavailable	Unavailable	2 / 2
2026-10-06	Unavailable	Unavailable	2 / 2
2026-10-07	Unavailable	Unavailable	2 / 2
2026-10-08	Unavailable	Unavailable	2 / 2
2026-10-09	Unavailable	Unavailable	2 / 2
2026-10-10	Unavailable	Unavailable	2 / 2
2026-10-11	Unavailable	Unavailable	2 / 2
2026-10-12	Unavailable	Unavailable	2 / 2
2026-10-13	Unavailable	Unavailable	2 / 2
2026-10-14	Unavailable	Unavailable	2 / 2
2026-10-15	Unavailable	Unavailable	2 / 2
2026-10-16	Unavailable	Unavailable	2 / 2
2026-10-17	Unavailable	Unavailable	2 / 2
2026-10-18	Unavailable	Unavailable	2 / 2
2026-10-19	Unavailable	Unavailable	2 / 2
2026-10-20	Unavailable	Unavailable	2 / 2
2026-10-21	Unavailable	Unavailable	2 / 2
2026-10-22	Unavailable	Unavailable	2 / 2
2026-10-23	Unavailable	Unavailable	2 / 2
2026-10-24	Unavailable	Unavailable	2 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	4	0	0
2026-07-01	4	0	0
2026-08-01	4	0	0
2026-09-01	4	0	0
2026-10-01	3	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce losses and improve earningsDiluted EPS: $-0.05 per share
Revenue exceeds $10 million in Q3 and Q4 2026Published status: Broken
Achieve double-digit revenue growth in 2026Published status: Broken

Next proof point

Nov 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-67.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Stereotaxis, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk medical technology growth story, not a proven durable compounder, because the company is still loss-making. The multi-year view remains intact despite a recent earnings miss, but growth execution and product adoption need to continue.

What's priced into Stereotaxis, Inc.

STXS carries a durable premium versus peers, while the expectations-gap measure is strongly negative. The evidence tags current pricing as justified and shows no fragility gates, but the premium leaves the thesis dependent on sustained growth rather than current earnings strength.

What the fundamentals likely do

Near term, revenue growth has been consistent with management's stated goal, and management expects 2026 revenue to exceed $40 million. Robotic catheter revenue grew sequentially, while manufacturing expansion and new product sales are progressing; Robocath integration remains ongoing. Losses, a recent earnings miss, and a higher risk label keep execution risk high.

What Stereotaxis, Inc. hinges on

Over the next few quarters, the key test is whether commercial adoption and manufacturing capacity keep advancing without a guidance cut. Weakening employment data could increase recession concerns, while strong results and guidance from healthcare bellwethers could support sector momentum. Robocath integration is another important execution factor.